That “Secondary Manufacturing in the UK” section also stood out to me Beartrap. It seems pretty clear that when DCVax is approved by the MHRA (and the automated manufacturing process is approved), Northwest Bio does not intend to limit production capacity to only their modified grade C cleanroom at Sawston. It could take at least a year to build out an additional grade C cleanroom at Sawston, so by adding a secondary manufacturing facility, Northwest Bio would have the capacity to fulfill the patient demand very quickly in the UK, which may be several thousand patients per year. I anticipate that this could potentially begin by the second or third quarter next year. The technology transfer for an automated process is significantly faster than the transfer of a manual process, and could potentially be achieved in as little as three to six months.
I agree that the 10K made it sound as though Advent could potentially manufacture DCVax in another established GMP facility in addition to Sawston. This 10Q clarified that the plan would be for another company to manufacture DCVax in their own GMP facility “in another relatively low-cost region in the UK” and Advent would train their personnel. I personally doubt that this company would be a BP at this stage though.
While some of the other speculation about potential companies and locations seems reasonable, I will speculate that this company may actually be eXmoor Pharma Concepts. Recall that eXmoor is a relatively small, but extremely capable CDMO that consulted with Advent previously, and even commented via social media when Northwest Bio submitted their MAA. In the time since Northwest Bio submitted the marketing application, eXmoor has received a manufacturing license for a state-of-the art 65,000 square foot advanced therapies manufacturing facility, with four cleanroom suites (and 12,000 sq. ft. fallow space) located in Bristol, UK.
I don’t have time to list the multiple reasons this makes sense to me, but here’s some links for those interested:
Market Data 
Markets 
